Amiodarone-Induced Thyroid Dysfunction Dynamics

Amiodarone is a highly effective antiarrhythmic agent richly laden with iodine that exerts complex effects on thyroid physiology. Following initiation, the drug’s slow tissue release and iodine overload can precipitate both hypo- and hyperthyroid states, collectively termed amiodarone-induced thyroid dysfunction (AITD). Two main pathophysiological subtypes emerge: Type 1, characterised by iodine-driven excess hormone synthesis in a gland with underlying pathology; and Type 2, a destructive thyroiditis releasing preformed hormones. The temporal dynamics of onset vary widely, from weeks to years, complicating early detection. Clinical presentation ranges from subtle biochemical shifts to life-threatening thyrotoxicosis or profound hypothyroidism, posing a therapeutic dilemma in patients dependent on amiodarone for cardiac stability. Monitoring of thyroid-stimulating hormone and free hormone concentrations is essential, as is the choice between conservative, medical or radical interventions. Amiodarone-induced thyroid dysfunction remains a global concern, with implications for patient management, resource allocation and the development of individualised risk-stratification tools.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Research from all publishers

A multicentre retrospective study has demonstrated the power of explainable machine learning models to forecast individual risk of thyroid dysfunction in patients receiving amiodarone. By integrating baseline demographics, serial biochemical markers and treatment duration, advanced algorithms achieved high discrimination and enabled dynamic risk stratification. Key predictors included thyroid-stimulating hormone, free thyroxine and lipid profiles. Such predictive tools offer clinicians data-driven thresholds for intensified monitoring and may support personalised decision-making regarding amiodarone continuation or adjustment of surveillance intervals.

In parallel, a genetic association study has identified a DUOX1 missense mutation that confers increased susceptibility to Type 2 amiodarone-induced thyrotoxicosis. Carriers of the variant exhibited a more than threefold elevated risk of destructive thyroiditis under amiodarone exposure. This finding pioneers a move towards pharmacogenetic screening prior to amiodarone initiation, suggesting that individuals with high-risk genotypes may benefit from alternative antiarrhythmic strategies or closer endocrinological follow-up.

For patients who develop refractory or life-threatening thyrotoxicosis, a recent clinical series has assessed outcomes of urgent radical therapies. In cases where pharmacotherapy failed or severe cardiac compromise arose, total thyroidectomy and radioiodine (131-I) therapy were compared. Thyroidectomy proved safe in centres with cardiac anaesthetic expertise, while radioiodine offered a non-surgical alternative when anaesthetic risk was prohibitive. Timely selection between these modalities was shown to be critical to reducing mortality and optimising cardiac function recovery.

Amiodarone-Induced Thyroid Dysfunction Dynamics publication trend

The graph below shows the total number of articles in amiodarone-induced thyroid dysfunction dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Amiodarone-Induced Thyroid Dysfunction (AITD): A spectrum of hypo- or hyperthyroid states triggered by the iodine content and direct effects of amiodarone on the thyroid gland.

Type 1 AIT: Iodine-induced hyperthyroidism occurring in patients with pre-existing thyroid disease, leading to excessive hormone synthesis.

Type 2 AIT: A destructive thyroiditis in which amiodarone causes thyroid cell damage and unregulated release of preformed hormones.

Thyroid-Stimulating Hormone (TSH): A pituitary hormone that regulates thyroid hormone production; used as a primary screening marker for thyroid status.

Free Thyroxine (fT4): The unbound form of thyroxine measured in blood to assess thyroid hormone activity independent of binding proteins.

Machine Learning Model: A computational algorithm trained on clinical and biochemical data to predict individual risk of AITD over time.

DUOX1 Gene: A gene encoding a key enzyme in thyroid hormone synthesis; certain mutations may predispose to thyroiditis under iodine excess.

Thyroidectomy: Surgical removal of the thyroid gland, employed as definitive treatment for refractory or life-threatening amiodarone-induced thyrotoxicosis.

Radioiodine (131-I) Therapy: A non-surgical approach using radioactive iodine to ablate thyroid tissue when surgery is contraindicated.

References

1. Explainable Machine Learning Techniques To Predict Amiodarone-Induced Thyroid Dysfunction Risk: Multicenter, Retrospective Study With External Validation. Journal of Medical Internet Research (2023).
2. DUOX1 Gene Missense Mutation Confers Susceptibility on Type 2 Amiodarone-Induced Thyrotoxicosis. International Journal of Molecular Sciences (2023).
3. Life-threatening amiodarone-induced thyrotoxicosis – Personalized approach to radical treatment. Heliyon (2024).